TABLE 5. Consumption of 6 selected antibiotics for the periods before (March 2018–July 2019) and during the COVID-19 pandemic (March 2020–July 2021) in intensive care units (ICUs) and non-ICU settings in 31 tertiary hospitals, stratified by type and location of hospitals, in Valle del Cauca, Colombia.
|
Antibiotic |
DDD daily defined doses per 100 bed-days |
|||
|---|---|---|---|---|
|
ICU |
Non-ICU |
|||
|
Before pandemic |
During pandemic |
Before pandemic |
During pandemic |
|
|
Ceftriaxone |
|
|
|
|
|
Overall |
2.7 |
2.9 |
16.0 |
16.4 |
|
Principal city |
3.2 |
3.3 |
8.1 |
5.8 |
|
Other cities |
2.1 |
3.4 |
21.2 |
24.3 |
|
Public |
0.2 |
0.6 |
25.4 |
29.3 |
|
Private |
2.9 |
3.1 |
6.6 |
5.3 |
|
Cefepime |
|
|
|
|
|
Overall |
5.6 |
6.3 |
1.9 |
2.2 |
|
Principal city |
5.1 |
6.9 |
3.5 |
3.7 |
|
Other cities |
3.4 |
6.1 |
0.8 |
1.0 |
|
Public |
6.3 |
12.7 |
0.6 |
1.0 |
|
Private |
5.5 |
5.7 |
2.8 |
3.1 |
|
Piperacillin/tazobactam |
|
|
|
|
|
Overall |
11.2 |
14.6 |
4.0 |
5.3 |
|
Principal city |
13.0 |
15.0 |
6.1 |
7.1 |
|
Other cities |
8.5 |
21.9 |
2.3 |
3.9 |
|
Public |
9.2 |
10.7 |
2.0 |
1.9 |
|
Private |
11.5 |
14.9 |
5.4 |
7.9 |
|
Ciprofloxacin |
|
|
|
|
|
Overall |
-- |
-- |
4.1 |
4.3 |
|
Principal city |
-- |
-- |
5.7 |
5.8 |
|
Other cities |
-- |
-- |
2.8 |
3.0 |
|
Public |
-- |
-- |
1.8 |
1.8 |
|
Private |
-- |
-- |
5.8 |
6.1 |
|
Meropenem |
|
|
|
|
|
Overall |
23.6 |
18.5 |
8.2 |
7.1 |
|
Principal city |
13.9 |
20.5 |
3.4 |
3.1 |
|
Other cities |
21.5 |
19.2 |
11.4 |
10.0 |
|
Public |
30.5 |
18.4 |
11.2 |
10.0 |
|
Private |
28.3 |
18.6 |
5.6 |
4.8 |
|
Vancomycin |
|
|
|
|
|
Overall |
10.8 |
12.6 |
2.6 |
3.2 |
|
Principal city |
12.2 |
14.3 |
3.8 |
4.4 |
|
Other cities |
8.2 |
11.2 |
1.6 |
2.2 |
|
Public |
10.9 |
10.6 |
1.2 |
1.5 |
|
Private |
10.7 |
12.8 |
3.6 |
4.4 |
Note: -- no data.
Source: Prepared by the authors based on the study data.